Meeting
2022 ASCO Annual Meeting
A randomized phase III study assessing the efficacy of liquid biopsy in early diagnosis of recurrence and second malignancies in lung cancer survivors.
Authors
Sana Raoof
Memorial Sloan Kettering, New York, NY
Sana Raoof , Daniel Richard Gomez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Prevention of Primary and Secondary Malignancies
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS10617)
DOI
10.1200/JCO.2022.40.16_suppl.TPS10617
Abstract #
TPS10617
Poster Bd #
489b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Randomized phase III clinical trial of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms: Interim analysis.
First Author: Alberto Saita
Poster
2023 ASCO Annual Meeting
Clinical validity of TTMV-HPV DNA liquid biopsies for the diagnosis and surveillance of HPV-associated oropharyngeal carcinoma.
First Author: Scott A. Roof
Poster
2023 ASCO Annual Meeting
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).
First Author: Anne-Marie C. Dingemans
Poster
2022 ASCO Annual Meeting
Efficacy and safety of SER-109, an investigational microbiome therapeutic for recurrent clostridioides difficile infection: Data from ECOSPOR III, a phase 3 randomized trial.
First Author: Alla Paskovaty